TAK 259Alternative Names: TAK-259
Latest Information Update: 25 Mar 2017
At a glance
- Originator Takeda
- Mechanism of Action Alpha 1 adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Overactive bladder
Most Recent Events
- 04 Feb 2013 Discontinued - Phase-I for Overactive bladder in Japan (PO)
- 29 Jul 2011 Phase-I clinical trials in Overactive bladder in Japan (PO)